Physician profile
Michael Beyer
NPI 1144750399
$3,180.95
in general payments reported to CMS, 2019-2025
13 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $25.61 · 2021: $315 · 2022: $169 · 2023: $34.05 · 2024: $479 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,699.03 | 2019-2020 | |
| Alcon Vision LLC | $891.78 | 2019-2025 | Centurion, Tryptyr, Clareon |
| Sight Sciences, INC. | $208.33 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $111.00 | 2024 | Envista Mx60 Iol, Envista Aspire Iol |
| Johnson & Johnson Surgical Vision, INC. | $62.40 | 2023-2025 | |
| Rxsight INC | $36.54 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Abbvie INC. | $30.17 | 2023-2024 | Alphagan P, Lumigan |
| Novartis Pharmaceuticals Corporation | $28.37 | 2019 | |
| Rayner Intraocular Lenses Limited | $27.04 | 2024 | Rayone Emv, Rayone Aspheric, Omidria |
| Thea Pharma INC. | $24.85 | 2022 | |
| New World Medical,INC. | $24.11 | 2022 | |
| Oyster Point Pharma, INC. | $19.17 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $18.16 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Beyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.